Evidence map›Paper›PMID 25330299›Full record

ArticleThe Journal of investigative dermatology2015

Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita.

Misa Hirose, Benjamin Tiburzy, Norito Ishii, Elena Pipi, Sabina Wende, Ellen Rentz, Falk Nimmerjahn, Detlef Zillikens, Rudolf A Manz, Ralf J Ludwig and 1 more

Open access · bronzeAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Mechanisms of Autoantibody-Induced Pathology.Frontiers in immunology · 2017
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Misa HiroseDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Benjamin TiburzyInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Norito IshiiDepartment of Dermatology, Kurume Medical University, Kurume, Japan.
Elena PipiDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Sabina WendeDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Ellen RentzBiotest Inc., Dreieich, Germany.
Falk NimmerjahnInstitute of Genetics, Department of Biology, University of Erlangen-Nuremberg, Erlangen, Germany.
Detlef ZillikensDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Rudolf A ManzInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Ralf J LudwigDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Michael KasperkiewiczDepartment of Dermatology, University of Lübeck, Lübeck, Germany. Electronic address: Michael.Kasperkiewicz@uksh.de.
University of Lübeck · DEBiotest (Germany) · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEKurume University Medical Center · JPUniversitäres Kinderwunschzentrum Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although well-designed prospective trials are generally lacking, intravenous immunoglobulins (IVIG) seem an effective adjuvant treatment for autoimmune bullous skin diseases. Here, efficacy of IVIG monotherapy was compared with corticosteroid treatment in mice with immunization-induced experimental epidermolysis bullosa acquisita (EBA), an autoimmune bullous skin disease characterized by autoantibodies against type VII collagen. We found that IVIG significantly ameliorated clinical disease severity and skin neutrophil infiltration compared with vehicle-treated mice, whereas methylprednisolone showed comparatively less pronounced effects. Efficacy of IVIG was accompanied by reduced levels of autoantibodies, a shift toward noncomplement-fixing autoantibodies, and lower complement deposition at the dermal-epidermal junction. In addition, peripheral Gr-1-positive cells of IVIG-treated animals showed reduced expression of the activating Fcγ receptor IV, which we recently described as a major mediator of tissue injury in experimental EBA. These data show that treatment with IVIG is superior to systemic corticosteroids in experimental EBA and that the effects of IVIG are pleiotropic involving modulation of both the adaptive and innate immune response, although the detailed mode of action of IVIG in this model remains in need of further elucidation.

Indexed as

Severity of Illness IndexAdrenal Cortex HormonesAnimalsAutoantibodiesCollagen Type VIIDisease Models, AnimalEpidermolysis Bullosa AcquisitaImmunoglobulins, IntravenousMiceMice, Mutant StrainsReceptors, Cell SurfaceReceptors, IgGTreatment OutcomeAdrenal Cortex HormonesAutoantibodiesCollagen Type VIIFcgr4 protein, mousegranulocyte receptor 1, mouseImmunoglobulins, IntravenousReceptors, Cell SurfaceReceptors, IgG

Identifiers

PMID25330299
OpenAlexW2071668217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.